Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2017-02-16 Interim / Quarterly Rep…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Half Yearly Report and Accounts 23 pages 196.3KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'ASX Half year report – 31 December 2016' and references the half-year ended 31 December 2016, with comparisons to the previous half-year period. It includes detailed financial statements such as consolidated income statement, balance sheet, cash flows, notes, directors' report, and auditor's review report. The content includes comprehensive financial data and analysis for a period shorter than a full fiscal year, consistent with an interim or quarterly report. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. The presence of detailed financial statements and management discussion confirms it is an Interim / Quarterly Report (IR). H1 2017
2017-02-16 English
Updated Investor Presentation 23 pages 838.3KB
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation' and contains detailed information about the company's business overview, drug development pipeline, partnerships, management team, financial strength, and strategic plans. It includes forward-looking statements, product portfolio details, and collaboration information. The content is typical of a presentation aimed at investors to provide insights into the company's operations, strategy, and financial position. There is no indication that this is a formal regulatory filing like an annual report or earnings release, nor is it a transcript or legal proceeding. The length and detail confirm it is a full presentation document rather than a brief announcement or summary. Therefore, the document fits the category of an Investor Presentation (IP).
2017-02-12 English
Appendix 4C - quarterly 5 pages 102.0KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B' and contains detailed consolidated cash flow statements for the current quarter and year-to-date six months, including operating, investing, and financing activities. It also includes payments to directors, financing facilities, estimated cash outflows for the next quarter, and a compliance statement signed by the CFO. The content is comprehensive and contains substantive financial data for a period shorter than a full fiscal year, consistent with an interim or quarterly report. The reference to Listing Rule 4.7B and the detailed financial data confirm this is a quarterly report rather than an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q2 2016
2017-01-29 English
Quarterly Report to Shareholders - December 2016 10 pages 419.2KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Shareholder Update – December 2016' and contains detailed discussion of business progress, drug development pipeline, clinical trials, milestone payments, sales updates, and future outlook. It includes substantive financial and operational data for a quarter, such as milestone payments expected, sales figures for Bronchitol in various markets, clinical trial progress, and collaboration updates. The content is comprehensive and covers a period shorter than a full fiscal year, consistent with a quarterly report. There is no indication that this is merely an announcement or a presentation, nor is it a transcript or a regulatory filing of a different nature. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q2 2017
2017-01-29 English
Appendix 3B - Exercise of Employee Options 11 pages 134.8KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3B' and is an announcement related to the issue of new securities, specifically the issuance of fully paid ordinary shares upon exercise of options under an employee option plan. It includes detailed information about the class, number, terms, and purpose of the securities issued, as well as references to ASX rules and compliance. There is no financial performance data, earnings information, or management discussion. The document is a formal announcement of a capital change event (new share issue) rather than a report or presentation. Therefore, it fits the category of 'Share Issue/Capital Change' (SHA). The document length is substantial and contains detailed issuance information, supporting a high confidence classification.
2017-01-24 English
Appendix 3B - Exercise of Employee Options 11 pages 134.8KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and references ASX rules related to securities issuance and quotation. It details the issuance of fully paid ordinary shares, exercise of options under an employee option plan, and includes information about the number and class of securities, issue price, purpose, and quotation agreement with ASX. The content is consistent with a formal announcement of new securities issuance and application for quotation on the ASX, rather than a financial report or earnings release. The document length is over 13,000 characters, indicating it is a full announcement rather than a brief notice. This matches the definition of a Share Issue/Capital Change filing, which covers announcements regarding new share issues and capital changes.
2016-12-11 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.